ruthenium ru 106

Drug Overview

Ruthenium Ru 106 is a highly specialized, radioactive treatment used in eye cancer care. It is not a pill or a liquid that goes into your bloodstream. Instead, it is a radioactive metal that is built into a small, bowl-shaped disc called a “plaque.” This treatment is a highly precise form of physical Targeted Therapy known as brachytherapy (internal radiation).

In the international medical community, Ruthenium Ru 106 is considered a gold standard for treating certain small to medium-sized eye tumors. Doctors surgically sew this tiny plaque to the outside of the eye, directly over the hidden tumor. It delivers powerful, cancer-killing energy straight into the tumor while sparing the healthy parts of the eye and the rest of the body.

• Generic name: Ruthenium Ru 106 (Ruthenium-106)
• US Brand names: Not applicable (Distributed as custom medical isotopes/plaques by specialized radiopharmacies, such as Eckert & Ziegler)
• Drug Class: Radioactive Isotope; Brachytherapy Source
• Route of Administration: Temporary surgical implant (Episcleral plaque)
• FDA Approval Status: FDA Approved (Regulated as a medical device/radioisotope)

What Is It and How Does It Work? (Mechanism of Action)

To understand how Ruthenium Ru 106 works, you have to look at how radioactive energy affects living cells. Ruthenium-106 is an unstable metal. As it breaks down (decays) into another metal called Rhodium-106, it releases energy in the form of “beta particles.” Beta particles are fast-moving electrons that only travel a very short distance (just a few millimeters).

Because these beta particles do not travel far, they are perfect for treating shallow eye tumors without sending radiation deep into the brain. At the molecular level, this is how it destroys the cancer:

1. Energy Release: The plaque is placed on the eye right over the tumor. It shoots beta particles directly into the cancer cells.
2. DNA Shattering: When these fast-moving particles hit the cancer cell, they crash into the cell’s DNA (its instruction manual). The energy causes direct “double-strand breaks,” meaning the DNA is completely shattered.
3. Free Radical Creation: The radiation also hits the water inside the cell, creating highly reactive chemicals called “free radicals.” These chemicals cause even more damage to the cancer cell’s internal machinery.
4. Cell Death (Apoptosis and Necrosis): Because the cancer cell’s DNA is broken beyond repair, it cannot divide or grow. The cell realizes it is fatally damaged and triggers a self-destruct sequence (apoptosis), or it simply dies from the heavy damage (necrosis).

FDA Approved Clinical Indications

Ruthenium Ru 106 is specifically approved and used for cancers located inside the eye (ocular oncology).

• Oncological uses:
  • Uveal Melanoma (Choroidal Melanoma): Small to medium-sized melanomas in the back of the eye.
  • Retinoblastoma: A rare childhood eye cancer (used for specific, localized tumors).
  • Conjunctival Melanoma: Cancer on the clear membrane covering the white part of the eye.
• Non-oncological uses:
  • There are currently no FDA-approved non-oncological uses for this radioactive isotope.

Dosage and Administration Protocols

Because Ruthenium Ru 106 is a radioactive implant and not a liquid drug, the “dose” is measured in units of radiation called Grays (Gy). The plaque is surgically sewn to the eye while the patient is asleep, left in place for a few days, and then surgically removed.

Dose Adjustments for Insufficiency:

• Renal/Hepatic Insufficiency: Because Ruthenium Ru 106 is a solid metal disc attached to the outside of the eye, the radiation does not travel through the bloodstream, liver, or kidneys. Therefore, no dose adjustments are needed for patients with liver or kidney disease.

Clinical Efficacy and Research Results

Recent clinical data from 2020 to 2025 confirms that Ruthenium-106 brachytherapy is highly successful at saving both the patient’s life and their eye.

• Tumor Control: Studies show that Ruthenium-106 provides excellent local tumor control. In over 90% to 95% of cases involving small to medium uveal melanomas, the radiation successfully stops the tumor from growing or shrinks it permanently.
• Eye Preservation: Before plaque therapy, the only treatment for eye cancer was completely removing the eye (enucleation). Today, numerical data shows that over 85% of patients treated with Ruthenium-106 get to keep their eye.
• Visual Outcomes: Because beta radiation does not penetrate very deeply, it is less likely to damage the optic nerve compared to other radiation types. Recent 2024 data shows that many patients retain useful vision in the treated eye, depending on exactly where the tumor was located.

Safety Profile and Side Effects

Black Box Warning:

None. (As a radioactive isotope/device, it does not carry a standard FDA pharmaceutical Black Box Warning, but it is handled under extremely strict hospital radiation safety laws).

Common side effects (>10%)

• Dry Eye Syndrome: A feeling of scratchiness or dryness in the treated eye.
• Cataracts: Clouding of the eye’s natural lens, causing blurry vision over time.
• Radiation Retinopathy: Damage to the tiny blood vessels in the back of the eye, which can cause bleeding or fluid buildup.
• Macular Edema: Swelling in the center of the retina, leading to blurry or wavy vision.

Serious adverse events

• Scleral Necrosis: Thinning or melting of the white part of the eye (sclera) where the plaque was attached.
• Optic Neuropathy: Radiation damage to the main optic nerve, which can lead to permanent vision loss in that eye.
• Secondary Glaucoma: A severe increase in eye pressure that can cause pain and vision loss.

Management strategies

• Vision Protection: If cataracts form, they can usually be fixed with standard, safe cataract surgery once the cancer is gone.
• Eye Injections: If radiation damages the blood vessels (retinopathy), doctors can give special medicine shots into the eye (like anti-VEGF drugs) to stop the bleeding and preserve vision.

Research Areas

In the fields of modern oncology, researchers are currently studying how to combine the localized power of Ruthenium Ru 106 with systemic Immunotherapy. While the radiation plaque effectively destroys the tumor inside the eye, uveal melanoma has a high risk of spreading (metastasizing) to the liver through the bloodstream. Current clinical trials (2024-2025) are testing if giving patients immune-boosting drugs (like tebentafusp) shortly after their Ruthenium-106 plaque is removed can help the immune system hunt down any microscopic cancer cells that may have escaped the eye, preventing future spread.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Ocular Ultrasound: To exactly measure the height and width of the tumor so the medical physicist can calculate the perfect radiation dose.
• Fundus Photography and OCT: High-definition pictures of the back of the eye to map exactly where the tumor sits.
• General Blood Tests: To ensure you are healthy enough for the two short surgeries (one to put the plaque in, and one to take it out).

Precautions during treatment

• Radiation Safety: While the plaque is on your eye, you will likely stay in a private hospital room. The plaque has a built-in shield, meaning very little radiation escapes your eye, but you will still need to limit close contact (hugging) with pregnant women and young children for those few days.
• Eye Patch: Your eye will be covered with a protective patch and shield while the plaque is in place. Do not touch or rub the eye.

“Do’s and Don’ts” list

• Do use all prescribed antibiotic and steroid eye drops exactly as your doctor tells you after the plaque is removed to prevent infection and heal the eye.
• Do attend all follow-up appointments. The tumor takes months to shrink, and your doctor needs to check your eye pressure regularly.
• Don’t rub, press, or put pressure on the treated eye while it is healing from surgery.
• Don’t skip your liver ultrasound check-ups. Even after the eye tumor is dead, your oncologist will need to scan your liver once or twice a year to ensure nothing has spread.

Legal Disclaimer

Standard medical information disclaimer: This guide is intended for educational and informational purposes only and does not constitute medical advice. Ruthenium Ru 106 is a radioactive medical treatment that must be administered by a highly specialized ocular oncologist and radiation oncologist. Always consult with your healthcare provider to discuss your specific diagnosis, treatment plan, and any potential risks. This content reflects clinical and research data available as of 2026.